The abstract that I am involved with in metastatic non-small cell lung cancer that is being presented at this meeting is an analysis of subgroups from the IMpower132 clinical trial which is a randomised clinical trial comparing standard non-squamous chemotherapy, platinum pemetrexed, with platinum pemetrexed and the addition of atezolizumab. I reported these results at the World Lung Meeting this year, the primary analysis included progression free survival, investigator assessed, and the investigational regimen containing atezolizumab was superior to standard platinum chemotherapy. Overall survival analysis data were not mature, they were numerically superior for the investigational arm.

In this meeting Dr Fabrice Barlesi is reporting subgroup analyses from this trial with some interesting findings pertaining to benefit in patients of Asian origin, older patients and patients that are never smokers.